Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org February 9, 2026 Philippe Henry preprint
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatments like SSRIs, SNRIs, and TCAs often require weeks for efficacy and do not address synaptic atrophy or the rapid "reset" of the Default Mode Network (DMN) required for immediate relief. While 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shows rapid...